Revenue Breakdown
Composition ()
No data
Revenue Streams
Amneal Pharmaceuticals Inc (AMRX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Oral solid, accounting for 24.6% of total sales, equivalent to $178.26M. Other significant revenue streams include Distribution and Central Nervous System. Understanding this composition is critical for investors evaluating how AMRX navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Amneal Pharmaceuticals Inc maintains a gross margin of 36.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.16%, while the net margin is 6.09%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively AMRX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, AMRX competes directly with industry leaders such as CRNX and GPCR. With a market capitalization of $4.34B, it holds a significant position in the sector. When comparing efficiency, AMRX's gross margin of 36.50% stands against CRNX's 82.54% and GPCR's N/A. Such benchmarking helps identify whether Amneal Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
